Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications.

IF 4.6 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-04-07 DOI:10.1007/s10787-025-01727-9

Xufan Sun, Guiyuan Jin, Huihui Zhou, Yan Wang, Fengxian Dai, Guangxi Zhou

{"title":"Role of guanylate-binding protein 5 in inflammatory diseases, immune diseases, cancers, and its potential therapeutic implications.","authors":"Xufan Sun, Guiyuan Jin, Huihui Zhou, Yan Wang, Fengxian Dai, Guangxi Zhou","doi":"10.1007/s10787-025-01727-9","DOIUrl":null,"url":null,"abstract":"<p><p>Guanylate-binding protein 5 (GBP5) is an interferon-γ (IFN-γ)-induced GTPase (Guanosine Triphosphatease) family member. It contains highly conserved guanosine triphosphate (GTP)-binding and hydrolysis domains, particularly within myeloid and T cells. Extensive research has underscored the critical role of GBP5 in various biological processes, including inflammation, cancer cell migration, and viral defence. In addition, GBP5 is involved in a range of physiological processes and is implicated in various pathological conditions, including inflammation and immune-related disorders. Recent studies have revealed the significant role of GBP5 in the initiation and progression of cancer. The impact of GBP5 on cancer varies depending on the specific cancer type and its underlying mechanisms of action. GBP5 can modulate multiple signalling pathways, including those involved in cell proliferation, cell cycle regulation, invasive metastasis, and the maintenance of homeostasis in vivo, all of which contribute to the progression of cancer. Consequently, in addition to functioning as a downstream molecule in the IFN-γ signalling pathway, GBP5 can influence the onset and progression of various diseases. This article examines the role of GBP5 in inflammation, autoimmune disorders, and malignancies while also exploring its potential therapeutic implications. We aim to deepen our understanding of GBP5 and assess its prospective applications in clinical diagnosis and treatment.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01727-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Guanylate-binding protein 5 (GBP5) is an interferon-γ (IFN-γ)-induced GTPase (Guanosine Triphosphatease) family member. It contains highly conserved guanosine triphosphate (GTP)-binding and hydrolysis domains, particularly within myeloid and T cells. Extensive research has underscored the critical role of GBP5 in various biological processes, including inflammation, cancer cell migration, and viral defence. In addition, GBP5 is involved in a range of physiological processes and is implicated in various pathological conditions, including inflammation and immune-related disorders. Recent studies have revealed the significant role of GBP5 in the initiation and progression of cancer. The impact of GBP5 on cancer varies depending on the specific cancer type and its underlying mechanisms of action. GBP5 can modulate multiple signalling pathways, including those involved in cell proliferation, cell cycle regulation, invasive metastasis, and the maintenance of homeostasis in vivo, all of which contribute to the progression of cancer. Consequently, in addition to functioning as a downstream molecule in the IFN-γ signalling pathway, GBP5 can influence the onset and progression of various diseases. This article examines the role of GBP5 in inflammation, autoimmune disorders, and malignancies while also exploring its potential therapeutic implications. We aim to deepen our understanding of GBP5 and assess its prospective applications in clinical diagnosis and treatment.

查看原文本刊更多论文

鸟苷酸结合蛋白5在炎症性疾病、免疫性疾病、癌症中的作用及其潜在的治疗意义

鸟苷结合蛋白5 （GBP5）是干扰素-γ (IFN-γ)诱导的鸟苷三磷酸酶（GTPase）家族成员。它含有高度保守的鸟苷三磷酸（GTP）结合和水解结构域，特别是在髓细胞和T细胞中。广泛的研究强调了GBP5在各种生物过程中的关键作用，包括炎症、癌细胞迁移和病毒防御。此外，GBP5参与一系列生理过程，并涉及多种病理状况，包括炎症和免疫相关疾病。最近的研究揭示了GBP5在癌症的发生和发展中的重要作用。GBP5对癌症的影响取决于特定的癌症类型及其潜在的作用机制。GBP5可以调节多种信号通路，包括参与细胞增殖、细胞周期调节、侵袭性转移和体内稳态维持的信号通路，这些信号通路都有助于癌症的进展。因此，除了作为IFN-γ信号通路的下游分子外，GBP5还可以影响各种疾病的发生和进展。本文探讨了GBP5在炎症、自身免疫性疾病和恶性肿瘤中的作用，同时也探讨了其潜在的治疗意义。我们旨在加深对GBP5的认识，并评估其在临床诊断和治疗中的应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]